Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders
09 janv. 2023 07h00 HE
|
Lupin Ltd
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables sustainable...
Creating a better plant-protein ingredient
17 mars 2022 12h00 HE
|
Protein Industries Canada
BOWDEN, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Protein Industries Canada and a consortium of partners, including More Than Protein Ingredients Ltd., Quantum Mechanical Technology Inc. and...
UPCOMING ANNOUNCEMENT: Creating a better plant-protein ingredient
15 mars 2022 16h00 HE
|
Protein Industries Canada
BOWDEN, Alberta, March 15, 2022 (GLOBE NEWSWIRE) -- More Than Protein Ingredients Ltd., Quantum Mechanical Technology Inc. and Hamman Ag Research Inc., with the support of Protein Industries Canada,...
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®
09 févr. 2022 07h23 HE
|
Lupin Ltd
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic...
New partnership to develop farm-to-fork ecosystem for lupin in Canada
16 déc. 2021 11h00 HE
|
Protein Industries Canada
CALGARY, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Today, Protein Industries Canada announced a project to establish lupin as a staple crop in the Canadian agrifood sector. Lupin Platform Inc., Hensall...
Global Prils Market is estimated to be US$ 3496.8 million by 2030 with a CAGR of 4.4% during the forecast period - by PMI
30 avr. 2021 10h35 HE
|
PMI
Covina, CA, April 30, 2021 (GLOBE NEWSWIRE) -- The Global Prils Market accounted for US$ 2388.6 million in 2020 and is estimated to be US$ 3496.8 million by 2030 and is anticipated to register a...
US FDA Grants Mexiletine Orphan Drug Designation
08 juin 2020 01h03 HE
|
Lupin Ltd
US FDA Grants Mexiletine Orphan Drug Designation Zug, Switzerland, 8 June 2019: Lupin is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)...